Comparison of Contrast Enhancement Pharmacokinetics of Contrast Media in Clinical Patients

1982 ◽  
pp. 314-318 ◽  
Author(s):  
M. Kormano ◽  
R. F. Spataro ◽  
S. Soimakallio ◽  
M. Wiljasalo
2018 ◽  
Vol 5 ◽  
pp. 183-188 ◽  
Author(s):  
Kuniharu Imai ◽  
Mitsuru Ikeda ◽  
Yoshiki Satoh ◽  
Keisuke Fujii ◽  
Chiyo Kawaura ◽  
...  

2008 ◽  
Vol 49 (3) ◽  
pp. 233-237 ◽  
Author(s):  
MIORI KISHIMOTO ◽  
KAZUTAKA YAMADA ◽  
RYO TSUNEDA ◽  
JUNICHIRO SHIMIZU ◽  
TOSHIROH IWASAKI ◽  
...  

1983 ◽  
Vol 18 (4) ◽  
pp. 368-374 ◽  
Author(s):  
PETER B. DEAN ◽  
LEENA KIVISAARI ◽  
MARTTI KORMANO

1988 ◽  
Vol 23 ◽  
pp. S118-S121 ◽  
Author(s):  
PETER B. DEAN ◽  
LEENA KIVISAARI ◽  
MARTTI KORMANO

2015 ◽  
Author(s):  
Pooyan Sahbaee ◽  
Yuan Li ◽  
Paul Segars ◽  
Daniele Marin ◽  
Rendon Nelson ◽  
...  

2011 ◽  
Vol 40 (3) ◽  
pp. 291-301 ◽  
Author(s):  
Seung-Man Yu ◽  
Kyung-Rae Dong ◽  
Youn-Sang Ji ◽  
Eun-Hoe Goo ◽  
Woon-Kwan Chung ◽  
...  

1995 ◽  
Vol 36 (4-6) ◽  
pp. 549-551
Author(s):  
Ö. Thorstensen ◽  
B. Isberg ◽  
P. Aspelin

The non-ionic monomeric contrast media iopamidol and iohexol were compared concerning enhancement in the organs of the upper abdomen in CT. The average peak enhancement above the base line for the 2 contrast media in the liver, vena cava, aorta and spleen was calculated. No difference between the contrast media was found with regard to increase in contrast enhancement. No correlation between the peak enhancement and body weight and body surface was found with either of the 2 contrast media.


2008 ◽  
Vol 47 (01) ◽  
pp. 30-36 ◽  
Author(s):  
M. L. Oei ◽  
M. Weckesser ◽  
C. Franzius ◽  
D. Wormanns ◽  
O. Schober ◽  
...  

SummaryAim: This study evaluated a MDCT protocol for contrast-enhanced 16-channel PET-CT with regard to scan range and duration of a whole-body 18F-FDG PET-CT examination, the occurrence of contrast-material induced artefacts and quantitative assessment of CT attenuation. Patients, methods: 205 patients (51.9 ± 12.4 years) with different malignant tumours underwent whole-body PET-CT; the study protocol had been approved by the institutional review board. Contrast-enhanced MDCT (16 ˟ 1.5 mm; 120 ml Iomeprol 3 ml/s, 50 ml saline chaser bolus, scan delay 70 s; oral contrast) was also used for attenuation correction. From MDCT data mean scan range and duration, occurrence of contrast media-induced artefacts, and mean CT densities of jugular (jv) and subclavian (scv), superior (vcs) and inferior (vci) caval, portal (pv), and bilateral external iliac veins, pulmonary (ap) and iliac arteries, descending thoracic and abdominal aorta, all cardiac chambers, as well as both liver lobes, spleen, adrenal glands and kidneys were determined. Results: Attenuation corrected PET images were free of contrast media-related image artefacts. Homogeneous contrast enhancement was found in the mediastinal veins (right/left jv 171 ± 34/171 ± 35, scv 127 ± 50/127 ± 40, vcs 153 ± 36 HU) and arteries (e.g. ap 145 ± 26/151 ± 26). Cardiac chambers, abdominal vessels (e.g. vci 138 ± 24, pv 159 ± 25 HU), and parenchymal organs revealed sufficient and homogenous contrast-enhancement in all cases. No beam-hardening artefacts occurred in the neighbourhood of the subclavian veins. Conclusion: The chosen whole-body 18F-FDG 16-slice PET-CT protocol allowed for craniocaudal CT scanning with high vessel and parenchymal contrast revealing no IV contrast-media induced artefacts in attenuation-corrected PET data sets.


Sign in / Sign up

Export Citation Format

Share Document